Exavir Therapeutics Completes $4M Seed Financing from Key Investors

Financing led by AlleyCorp with participation from Gilead Sciences to support the development of ultra-long-acting integrase inhibitors Financing led by AlleyCorp with participation from Gilead Sciences to support the development of ultra-long-acting integrase inhibitors

Mon, 23 May 2022 04:59 PM (IST)
 0
Exavir Therapeutics Completes $4M Seed Financing from Key Investors
Financing led by AlleyCorp with participation from Gilead Sciences to support the development of ultra-long-acting integrase inhibitors
Financing led by AlleyCorp with participation from Gilead Sciences to support the development of ultra-long-acting integrase inhibitors
Sangri Today Sangri Today is a Weekly Bilingual Newspaper and website of news and current affairs that publishes news reports from various places, from general reports.